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Aim. In Crohn’s disease (CD), anti-TNF-α treatment is a potent medication. We aimed to characterize the eﬀect of anti-TNF-α
treatment on T eﬀector and regulatory cells. Material and Methods. We studied T-eﬀector and regulatory cells on cellular and
mRNA levels in intestinal biopsy samples from 13 Crohn’s disease patient. Biopsies were obtained at baseline and 3 months after
anti-TNF-α treatment, and from 14 inflammation-free control subjects. Results. Patients had higher numbers of ileal IL-17+ and
forkhead box P3 (FOXP3)+ cells than did control subjects, both before ( P ≤ 0.001 and P ≤ 0.05, resp.) and after the anti-TNF-α
treatment (P ≤ 0.01, P ≤ 0.01). Intestinal interferon-γ and IL-17 mRNA expression was higher in Crohn’s disease and remained
elevated after anti-TNF-α treatment. The ratio of IL-17+ cells to CD4+ cells decreased (P ≤ 0.05) and compared to baseline the
ratio of IL-17+ cells to FOXP3+ was lower after treatment (P ≤ 0.05). Conclusions. TNF-α-blocking agents improved intestinal
balance between IL-17+ T-eﬀector and regulatory T cells, although intestinal IL-17 upregulation remained elevated.
1. Introduction
Chronic intestinal inflammation characterizes Crohn’s dis-
ease (CD), the etiology of which is incompletely understood,
but likely intestinal microflora components cause aberrant
immune responses. Discovery of NOD2 genetic polymor-
phism has identified CARD15 allele as a risk factor for
CD and supports the important role of the innate immune
system in CD pathogenesis. Interleukin 23 receptor (IL-
23R) gene polymorphisms associate with CD and provides a
link to Th17 immunity, a hallmark of CD [1–4]. IL-23 is a
cytokine important for the expansion and function of IL-
23R-expressing Th17 cells [5]. In CD, colonic and ileal biopsy
samples show IL-17+ cells [3, 4, 6].
Biological agents contribute to the repertoire of medical
treatment of CD: tumor necrosis factor- (TNF-) α blocking
therapy is eﬀective in inducting and maintaining remission
[7, 8]. In active CD, infliximab induces rapid clinical
improvement as well as rapid endoscopic and histological
healing [9]; unfortunately, the cessation of anti-TNF-α ther-
apy tends to lead to a disease relapse. Conventional therapies
fail to normalize the numbers of IL-17+ cells in the ileal
lamina propria (LP), even during endoscopic remission [4].
Colitogenic Th17 cells may be a factor behind the relapsing
nature of the disease [10]. Whether TNF-α-blocking therapy
normalizes the number of intestinal Th17 cells remains
unknown. Few studies of infliximab’s eﬀect on Th17 cells
exist in rheumatoid arthritis infliximab, which seems to
reduce peripheral Th17 cells [11].
Transcription factor FOXP3 characterizes regulatory T
cells (Tregs), a unique subset of T cells that regulate immune
response [12–14]. A few studies on Tregs and their role
in intestinal inflammation exist and most of them show a
consistent expansion of intestinal Tregs and suppressive Treg
activity in vitro [15–17]. In adult CD, however, the eﬀect
of TNF-α-blocking therapy on intestinal Tregs is unknown.
Further, in IBD, the balance between Th17 and Treg cells
plays an important role [10].
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2. Materials andMethods
2.1. Patients. In Helsinki University Central Hospital 13
adult patients with established CD twice underwent ileo-
colonoscopy: a baseline endoscopy and a treatment-response
evaluation at 12 weeks. The Crohn’s disease endoscopic index
of severity (CDEIS) served to grade the endoscopy findings:
scores <3 suggested inactive disease and ≥3 endoscopically
active disease [18, 19]. The Crohn’s disease activity index
(CDAI) served to assess clinical activity [14]. At the time
of endoscopies, patients provided blood and fecal samples.
After the baseline endoscopy, all patients received anti-
TNF-α-therapy (median 7 days after, range 1–38 days). 12
received infliximab infusions 5mg/kg at weeks 0 and 8, and
one patient received an adalimumab induction dose 80mg
subcutaneously at week 0, followed by 40mg subcutaneously
every other week until week 8; thereafter she underwent
the second endoscopy at 10 weeks. Before the anti-TNF-α
therapy, maintenance therapy remained unchanged, there-
after corticosteroids were tapered oﬀ. Table 1 shows patient
characteristics.
The control group comprised 14 patients referred to ileo-
colonoscopy for the following indications: change in bowel
habits in 3, diverticular disease, colorectal cancer followup,
history of adenoma, and rectal bleeding (2 with each),
history of polyps in one, exclusion of CD in one patient
with history of perianal abscesses, and in one patient with
abdominal pain. In routine histological analysis of biopsies,
all control subjects showed normal findings.
2.2. Immunoenzymatic Labeling and Microscopic Evaluation.
During endoscopies, twomucosal biopsies were taken, frozen
in OCT, and stored at −70◦C. For immunohistochemical
staining, 7 μm sections were cut, with the avidin-biotin
immunoperoxidase system applied according to the Vectas-
tain ABC Elite kit (Vector Laboratories, Peterborough, UK)
instructions. The acetone-fixed slides were blocked in normal
serum for 30 minutes. We incubated slides for 1 hour with
either monoclonal mouse anti-human CD4 (BD Pharmin-
gen, San Diego, CA, USA), CD8 (Dakocytomation, Glostrup
Denmark), FOXP3 (Abcam, Cambridge, UK), or polyclonal
rabbit anti-human IL-17 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) antibodies. Then the slides were incubated
in biotinylated antibody and ABC reagent. AEC served as
a chromogen and hematoxylin served to counterstain the
slides. Omission of the primary antibodies served as the
negative control. The numbers of positively stained LP cells
were counted under a Leica DM4000B light microscope
through a calibrated graticule. In each specimen, positive
cells were expressed as the mean number of cells/mm2.
2.3. Fecal Calprotectin Assays. The values quoted as normal
fecal calprotectin were <100 μg/g of stool [15, 16] and were
measured by a quantitative enzyme immunoassay (PhiCal
Test, Calpro AS, Oslo, Norway).
2.4. Quantitative Real-Time PCR. Total RNA was extracted
from biopsies with the GenElute Mammalian total RNA
miniprep kit (Sigma, St. Louis, MO, USA) and reverse
Table 1: Patient characteristics.
n
Gender: female/male 6/7 (46/54%)
Disease type
Inflammatory 6 (46%)
Stricturing 4 (31%)
Inflammatory + perianal 3 (23%)
Disease location
Ileum 2 (15%)
Colon 3 (23%)
Ileocolon 8 (62%)
Medication (at first endoscopy)
Azathioprine or 6- 9 (69%)
mercaptopurin 2 (15%)
Methotrexate 9 (69%)
Corticosteroids 9 (69%)
Mesalamine 2 (15%)
Salazosulphapyridine 1 (8%)
Metronidazole
Medication (at second endoscopy)
Azathioprine or 6- 11 (85%)
mercaptopurin 2 (15%)
Methotrexate 0 (0%)
Corticosteroids 8 (62%)
Mesalamine 2 (15%)
Salazosulphapyridine 0 (0%)
Metronidazole
Previous anti-TNF-α 4 (31%)
treatment
Median (range)
Age, years, 23 (19–44)
Disease duration, years 5.1 (0.4–27.0)
CDEIS
Before treatment 14.4 (1.8–25.3)
After treatment 4.4 (0.0–11.2), P = 0.006
CDAI
Before treatment 174 (50–605)
After treatment 64 (24–112), P = 0.003
Fecal calprotectin μg/g
Before treatment 1173 (88–15326)
After treatment 127 (13–1419), P = 0.002
Serum CRP
Before treatment (n = 10) 8 (<5–42)
After treatment <5 (<5-6), P = 0.012
CDAI: Crohn’s disease activity index; CDEIS: Crohn’s disease index of
severity.
transcribed as earlier described [4]. QPCR runs with cDNA
samples and TaqMan reagents (Applied Biosystems) were
performed in triplicate on the StepOnePlus RT-PCR system
(Applied Biosystems) programmed for an initial step of 20
seconds at 95◦C, followed by 40 thermal cycles of 1 second
at 95◦C and 20 seconds at 60◦C. Raw data were analyzed
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Figure 1: Immunoperoxidase staining for forkhead box P3 (FOXP3) and interleukin 17 (IL-17) in frozen sections, 3-amino-9-
ethylcarbazole-hematoxylin stain. Staining of FOXP3 in mucosal biopsy specimens from a control patient (a), original magnification 200x.
Representative stainings for FOXP3 (b, nuclear) and IL-17 (c, paranuclear) from a Crohn’s disease patient. Scale bar indicates 50 μm, original
magnifications 100x and 200x. Insets: FOXP3 (b) and IL-17 (c), original magnification 1000x.
as previously described [4]. Target-specific primers/probes
were IL-17A, FOXP3, IL-23A p19, TNF-α, and 18s (Applied
Biosystems). Ribosomal 18s RNA served as the endogenous
control.
2.5. Statistical Analysis. For all studies, data are expressed
as median (range). The nonparametric Kruskal-Wallis test,
the Mann-Whitney U-test, Wilcoxon signed rank test, and
Spearman’s correlation served for statistical analyses (SPSS,
v14.0; SPSS Inc, Chicago, IL, USA). A P value < 0.05 was
considered significant.
2.6. Ethical Considerations. The Ethics Committee, Depart-
ment of Medicine, Helsinki University Central Hospital,
Helsinki, approved the study plan. All patients and control
subjects gave their informed written consent to participate
in this study.
3. Results
3.1. IL-17+, FOXP3+, CD4+, and CD8+ Cells in Biopsy Sam-
ples. Figure 1 shows IL-17 and FOXP3 stainings. For statisti-
cal analyses, patients with disease localization diﬀering from
the sample site were excluded. The number of ileal IL-17+
cells was higher in CD than in the control subjects before and
after treatment (P < 0.0005 and 0.005, Mann-Whitney U-
test, Figure 2(a)), and the number of ileal FOXP3+ cells was
higher in patients’ samples both before and after treatment
(P = 0.023 and 0.005, Figure 2(b)). The number of colonic
IL-17+ cells was higher in CD at baseline and 3-month
follow-up samples than in controls (P = 0.015 and 0.042).
The number of colonic FOXP3+ cells was higher in CD in
the 3-month samples than in controls (P = 0.032). Numbers
of ileal or colonic CD4+ or CD8+ cells showed no diﬀerence.
In the parameters measured no diﬀerence emerged between
baseline and 3-month follow-up samples.
3.2. mRNA Expression in Biopsy Samples (Table 2). Colonic
IL-17 mRNA expression was higher in CD than in controls
at baseline (P = 0.038), but not after treatment. Ileal
IL-23 mRNA expression was higher both before and after
treatment (P = 0.037 and 0.022). In CD, ileal and colonic
IFN-γ, along with ileal FOXP3 mRNA expression showed an
increase before and after treatment.
3.3. Relative Number of IL-17+ Cells or FOXP3+ Cells of CD4+
and CD8+ Cells. Compared to the controls, the patients
showed an increased ratio of ileal IL-17+ cells to CD4+ cells
in both samples (P = 0.0006 and 0.0013, Figure 3). Anti-
TNF-α treatment reduced significantly the ratio of IL-17+
cells to CD4+ cells (P = 0.047, Wilcoxon signed rank test). In
both samples, the ratio of ileal IL-17+ cells to CD8+ cells was
higher in CD than in controls (P = 0.0001 and P = 0.0031).
The ratio of ileal FOXP3+ cells to CD4+ cells was higher in
both samples in CD than in controls (P = 0.03 and 0.03).
In the parameters measured no diﬀerence appeared between
the two samples.
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Figure 2: Changes in numbers of IL-17+ and FOXP3+ cells in ileal biopsy samples taken before 0 and 3months after beginning of anti-TNF-α
treatment (a, b).
0
1
2
2
12
0 month 3 months Controls
P = 0.0006
P = 0.0013
P = 0.0047
IL
-1
7+
/C
D
4+
(c
el
ls
/m
m
2
)
Figure 3: Ratio of IL-17+ cells to CD4+cells in ileal biopsy samples
in active CD before 0 and 3 months after beginning of anti-TNF-α
treatment and control subjects.
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Figure 4: Ratio of IL-17+ cells to FOXP3+ cells higher in 0-month
samples than in 3-month samples (P = 0.038, Mann-Whitney U-
test).
3.4. Relation between T Eﬀector and T Regulatory Cell Mark-
ers. The ratio of ileal IL-17+ cells to FOXP3+ cells was higher
at baseline than in 3-month samples (P = 0.038, Mann-
Whitney U-test, Figure 4). The ratio of ileal or colonic IL-
17 or IFN-γ mRNA expression to FOXP3 mRNA expression
showed no diﬀerence between the two samples. In CD, ileal
and colonic IFN-γ and IL-17 mRNA expression correlated
positively (r = 0.636; P = 0.026; r = 0.539; P = 0.021).
3.5. Correlation between CDEIS and Markers for T Eﬀector
or T Regulatory Cells. At treatment-response endoscopy ileal
IL-17+ cells and IL-17mRNA expression correlated positively
with CDEIS (r = 0.806, P = 0.007; r = 0.736, P = 0.038).
FOXP3+ or CD4+ cells and CDEIS showed no correlation,
but at baseline ileal FOXP3 mRNA expression and CDEIS
correlated positively (r = 0.830; P = 0.041).
4. Discussion
In CD, a marked decrease in CDEIS associated with a
decreasing ratio of intestinal IL-17+ cells related to the
numbers of CD4+ cells and FOXP3+ cells. These results
suggest that anti-TNF-α treatment leads to an improved
balance between regulatory T cells and IL-17 eﬀector T cells.
The relative upregulation of regulatory mechanisms is likely
the explanation for the clinical and endoscopic response to
treatment since the TNF-α blockade failed to normalize the
mucosal IL-17 or IFN-γ upregulation that is characteristic of
CD [3, 4]. These findings support the view of the synergistic
role of IL-17 and TNF-α in tissue damage. 3 months after
treatment, CDEIS correlated positively with magnitude of
intestinal IL-17 immunity, indicating that when the eﬀect
of TNF-α is blocked, the role of IL-17 in the intestinal
inflammation is clearly demonstrable. Before the anti-TNF-
α treatment, no such correlation existed between CDEIS
and IL-17 immunity. Accordingly, full endoscopic remission
associated with lower IL-17 activity after treatment, whereas
the only patient with increasing CDEIS during treatment
showed an increase also in her proportion of IL-17+ cells. On
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Table 2: mRNA expression of L-17, IL-23, FOXP3, IFN-γ and TNF-α in ileal and colonic biopsy samples taken before (0) and 3 months after
the beginning of anti-TNF-α treatment. Median (range) mRNA levels are expressed as relative units in relation to in-house calibrator (phy-
tohemagglutinin-stimulated peripheral blood monocytes). Asterix: statistically significant diﬀerences between patients and control subjects.
0 month 3 months Controls
Ileum
IL-17 128.0 (30–325) 67.5 (30–615) 30.0 (30–419)
IL-23 373.0 (322–804)∗ 444.5 (235–542)∗ 225.0 (153–706)
FOXP3 611.0 (15–792)∗ 104.5 (15–891)∗ 20.5 (15–220)
IFN-γ 19.6 (8.6–230)∗∗∗ 14.0 (1.00–37.6)∗ 1.0 (1.0–6.0)
TNF-α 38.7 (8.6–206.6) 43.7 (10.2–249.9) —
Colon
IL-17 133.5 (30–588)∗ 79.0 (30–1607) 30.0 (30–144)
IL-23 167.0 (72–405) 240.0 (74–983) 252.0 (9–392)
FOXP3 311.5 (63–694)∗∗ 135.5 (15–1284) 49.0 (15–252)
IFN-γ 45.0 (2.0–249.7)∗∗ 15.7 (1.0–122.2)∗ 1.0 (1.0–5.6)
TNF-α 30.9 (8.9–53.4) 23.9 (3.1–111.7) 18.8 (3.4–47.6)
∗P < 0.05,∗∗P < 0.01,∗∗∗P < 0.001, Mann-Whitney U-test.
the other hand, although anti-TNF-α treatment was unable
to downregulate directly the IL-23/IL-17 axis responsible
for mucosal damage, its beneficial eﬀect was mediated via
changes in the immunological network.
Full understanding of the relation between Th17 and
T regulatory cells is lacking. TNF-α suppresses the devel-
opment of Th17 cells from naı¨ve CD4 cells [20], but the
function of T regulatory cells complicates the interaction;
blocking the function of TNF-α does not downregulate IL-
17 immunity. This correlates with our findings suggesting
a relative decrease in IL-17 immunity in relation to total
number of CD4+ cells and FOXP3+ cells. In addition, IL-
17+ cells may arise from Tregs due to their plasticity. In the
presence of IL-6, CD4+CD25+FOXP3+ cells can diﬀerentiate
into Th17 [21], however, anti-TNF-α treatment reduces
IL-6 production and may inhibit this diﬀerentiation. The
beneficial change in the balance between IL-17+ and FOXP3+
cells may reflect this phenomenon.
Because CD4+CD25− cells can be induced to express
FOXP3 [22], intestinal FOXP3 expressing cells may be either
classical Treg or activated T cells. Activated FOXP3-express-
ing T cells are hyporesponsive, with impaired suppressive
function, and transient FOXP3 expression also exists in a
nonsuppressive T cell population [23]. Possibly in active CD,
T cell activation induces FOXP3 expression and thus does
not necessarily display suppressive capability. In remission, a
high number of FOXP3+ cells may, however, reflect the num-
ber of natural, suppressive T regulatory cells.
In evaluating the eﬀect of anti-TNF-α agents on im-
munological markers, changes in maintenance therapy are
important. Most of our patients received corticosteroid treat-
ment at the first administration of anti-TNF-α treatment, but
none at the time of the second colonoscopy. Corticosteroids
inhibit T cell activation by multiple mechanisms [24], pos-
sibly through induction of T regulatory cells. In asthma
patients receiving glucocorticoid treatment, FOXP3 mRNA
expression increases [25]. In keeping with this, we report
increased numbers of FOXP3+ cells in active disease, but here
FOXP3 was high also after treatment.
Especially in animal models for inflammatory bowel
disease, evidence accumulates regarding the importance of
the IL-23/IL-17 axis [26]. A unique subset of intestinal
macrophages producing proinflammatory cytokines such as
IL-23, TNF-α, and IL-6 exists [27]. In CD, the number of
these macrophages is higher and they contribute to IFN-
γ production by LP mononuclear cells rather than IL-17,
and IFN-γ triggers further abnormal macrophage diﬀeren-
tiation with hyperproduction of IL-23. Likewise, we showed
enhanced ileal IFN-γ mRNA expression in CD. Th1/Th17
mucosal cells and T cell lines able to secrete both IL-17
and IFN-γ have been described in CD related intestinal
inflammation [28, 29]. A positive correlation between IL-
17 and IFN-γ mRNA expression in ileal CD may reflect
activation of these kinds of cells. Possibly, Th1/Th17 cells
produced IL-17 and IFN-γ, but because we lacked material
to further characterize IL-17- or IFN-γ-producing cells, this
question remains open. Unfortunately, we were unable to
accomplish double-staining for IL-17 or FOXP3, and for
surface markers, due to lack of material.
Our data showed that mucosal healing induced by TNF-
α blocking treatment associates with beneficial changes in
the balance between regulatory and eﬀector T cells. The
presence of Th17 cells after the treatment suggests the need
for maintenance therapy to avoid the risk of relapse.
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